Clinical trials
B Cell Malignancies clinical trials
Below are recruiting b cell malignancies clinical trials, each written for real people, not researchers. We’re tracking 604 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04545762RecruitingPhase 1
Anti-CD19 CAR-T for certain relapsed lymphoma
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
San Francisco, CaliforniaAges 18 years+ - NCT06687772RecruitingPhase 2
Preventing brain relapse in high-risk lymphoma with stem cell transplant
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
St Louis, MissouriAges 18–75 - NCT06316427RecruitingPhase 1/Phase 2
CD7 CAR-T therapy for T-cell cancers that returned
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
Beijing, Beijing MunicipalityAges 1–70 - NCT05170399RecruitingPhase 4
Testing how cancer vaccines work in B-cell blood cancers
This study measures how well certain vaccines stimulate the immune system in people with B-cell blood cancers such as CLL and different types of lymphoma or Waldenström macroglobulinemia. It may help doctors better predict who will benefit most from vaccination and improve vaccine planning for these conditions.
Bethesda, MarylandAges 18–90 - NCT06834529RecruitingPhase 1/Phase 2
CAR-T cell therapy for returning B-cell leukemia or lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
Beijing, Beijing MunicipalityAges 14–75 - NCT07239323RecruitingPhase 1
CAR-T therapy for blood cancers that have returned or not responded
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
Kunming, YunnanAges 18 years+ - NCT05518383RecruitingPhase 4
Pediatric B-cell lymphoma treatment study using established care
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
Moscow, RFAges 1 day–18 years - NCT07838714RecruitingPhase 1
Cord blood CAR-T cells for relapsed B-cell leukemia
This trial tests a new type of personalized cell therapy using your own immune cells (called CAR-T cells) that are designed to find and attack leukemia cells that have certain markers (CD19 and CD22). It is for people whose leukemia has returned or not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06462365RecruitingPhase 1
Preventing GvHD after stem cell transplant for blood cancers
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Duarte, CaliforniaAges 18 years+ - NCT06461182RecruitingPhase 2
PET Scan Test for Slow-Growing Lymphoma
This trial uses a special PET scan to take detailed pictures of slow-growing lymphomas, likely before or after your regular treatment scan. It may help your doctor see exactly where the lymphoma is in your body.
Taipei, BeitouAges 20–100 - NCT07823829RecruitingPhase 1/Phase 2
CT1190B for large B-cell lymphoma that has returned or not responded to treatment
This study tests a new treatment called CT1190B for people with large B-cell lymphoma that has come back or hasn't responded to at least two prior treatments. The goal is to see if this treatment can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06517004RecruitingPhase 1
Study of JWCAR201 for relapsed or refractory large B-cell lymphoma
This trial tests a new cell therapy called JWCAR201 for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to at least two prior treatments. The goal is to see if this treatment can help when standard options have stopped working.
ShanghaiAges 18 years+ - NCT06609304RecruitingPhase 4
CAR T-cell therapy after first treatment for high-risk lymphoma
This trial tests whether a type of immunotherapy called axicabtagene ciloleucel (a CAR T-cell therapy) can improve outcomes when given right after initial treatment for high-risk large B-cell lymphoma. It is for people who have not yet started treatment.
Zhengzhou, HenanAges 18–70 - NCT05348213RecruitingPhase 2
Targeted drugs plus R-ICE chemo for relapsed lymphoma
This Phase 2 trial studies targeted drugs combined with R-ICE chemotherapy in people with diffuse large B-cell lymphoma (DLBCL) that has come back or hasn’t responded. It may help shrink the lymphoma after prior treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07371923RecruitingPhase 2
Zanubrutinib combination therapy for newly diagnosed high-risk DLBCL
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07316010RecruitingPhase 2
Liso-cel for lymphoma with minimal residual disease after first treatment
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
Houston, TexasAges 18 years+ - NCT07270835RecruitingPhase 4
Zanubrutinib plus rituximab for HLH with B-cell lymphoma
This study tests a combination of two drugs—zanubrutinib and rituximab—to treat HLH that happens in people with B-cell lymphoma. It aims to see if this treatment is safe and works better.
Suzhou, JiangsuAges 14–80 - NCT07124936RecruitingPhase 1/Phase 2
Study of new drug plus standard care for large B-cell lymphoma
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06829771RecruitingPhase 1/Phase 2
A new drug combined with standard chemo for large B-cell lymphoma
This trial is testing a new drug called TQB2825 given alongside standard chemotherapy (R-CHOP or GemOx) for people with diffuse large B-cell lymphoma (DLBCL) or a related type called grade 3b follicular lymphoma. The goal is to see if adding this new drug is safe and works better than standard treatment alone.
Bengbu, AnhuiAges 18–80 - NCT06792734RecruitingPhase 1
Testing BTM-3566 for lymphoma that has returned
This trial tests an experimental drug called BTM-3566 in people with a type of lymphoma that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Charlotte, North CarolinaAges 18 years+ - NCT06760156RecruitingPhase 2
Tafasitamab and Lenalidomide after CAR-T for Large B-cell Lymphoma
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
Tampa, FloridaAges 18 years+ - NCT05607420RecruitingPhase 1/Phase 2
Testing a new cell therapy for relapsed lymphoma with CD20/CD22
This Phase 1/2 trial studies UCART20x22, a lab-made cell therapy, for people with certain types of relapsed or treatment-resistant B-cell non-Hodgkin lymphoma (NHL). It may help by targeting lymphoma cells that carry CD20 and/or CD22 markers and then testing safety and early effectiveness.
Chicago, IllinoisAges 18–80 - NCT06485076Recruiting
Early comfort care for multiple myeloma and aggressive lymphoma
This study offers a palliative care team (doctors and nurses focused on comfort and quality of life) to people newly diagnosed with multiple myeloma or with an aggressive lymphoma that has come back. The goal is to help manage symptoms early, so you feel better and stay stronger during your cancer treatment.
Toronto, OntarioAges 18 years+ - NCT06045247RecruitingPhase 2
Epcoritamab with gentler chemo for older adults with lymphoma
This trial tests a combination of two drugs — epcoritamab and a gentler chemo regimen (rituximab-mini CVP) — for older or frailer patients with newly diagnosed aggressive B-cell lymphoma who cannot tolerate standard intensive chemo. The goal is to find a safer but effective treatment option that still controls the lymphoma.
Houston, TexasAges 18 years+
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for b cell malignancies?
- Yes. Clin2 currently lists 604 recruiting b cell malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a b cell malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a b cell malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.